All In MedTech

Device Trial Radar · NCT05127551

Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor

A Prospective, Randomized, Controlled, Comparitive Multicenter Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite® vs Competitor in Adult Subjects With Primary Open-Angle Glaucoma (POAG)

Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

179

Actual

Start

Nov 27, 2021

Primary completion

Feb 29, 2024

Study completion Feb 28, 2025

Sponsor

Lead sponsor
Glaukos CorporationPublic (GKOS)
Sponsor type
Industry
First posted
Nov 19, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor

Conditions

  • Glaucoma
  • Glaucoma, Open-Angle

Interventions

  • iStent InfiniteDevice

    Implantation of the iStent Infinite

  • Competitor DeviceDevice

    Implantation of competitor device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Mean Diurnal Intraocular PressureTime frame: Month 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Glaukos Investigator Sites

    Montreal, Qubec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.